Legend Biotech Corporation, a global biotechnology leader in developing, manufacturing and commercializing novel treatments for life-threatening diseases, today announced the appointment of Mythili Koneru, M.D., Ph.D. as the Company’s Chief Medical Officer. As CMO, Dr. Koneru will lead the charge in advancing Legend Biotech’s clinical development and medical affairs initiatives, helping to bring life-saving treatments to those in need.
Dr. Koneru brings a wealth of experience to Legend Biotech from her time as Chief Medical Officer at Marker Therapeutics, where she oversaw the development of cell therapies and peptide vaccines for immuno-oncology applications.
Prior to joining Marker, Dr. Koneru was Associate Vice President of Immuno-Oncology at Eli Lilly and Company, where she advanced the clinical development of immuno-oncology assets. Before that, she worked as an Oncology Fellow at Memorial Sloan-Kettering Cancer Center, where she developed cutting-edge adoptive T-cell therapies for leukemia and solid tumor malignancies in early phase clinical trials.
With great enthusiasm, Legend Biotech is pleased to welcome Dr. Koneru to the team! Boasting extensive expertise in immunotherapy and cell therapy, Dr. Koneru has designed early-stage clinical trials for hematologic malignancies and solid tumors.
We are confident that her leadership and contributions will be invaluable as we strive to advance our cell-based therapies and bring novel treatments to the clinic. CEO Ying Huang eagerly anticipates the insights and energy that Dr. Koneru will bring to the organization.
Dr. Koneru is a brilliant scholar who has achieved academic excellence in the fields of Cellular and Molecular Biology, Biomedical Research, and Tumor Immunology. She obtained her B.A. from the University of Chicago, her Ph.D. from New York University, and her M.D. from Robert Wood Johnson Medical School, making her a true master of the medical sciences.
About Legend Biotech
At Legend Biotech, we are driven by a mission to one day cure life-threatening diseases and bring hope to patients worldwide. We are leading the way in advanced cell therapy treatments, leveraging autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy at our three R&D sites located in Somerset, New Jersey and around the world. Our passionate team is committed to developing and delivering innovative therapies that can make a meaningful difference in the lives of those who are suffering.